ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

[18F] AlF-NOTA-FAPI-04 PET/CT as a promising tool for imaging fibroblast activation protein in gastrointestinal system cancers: a prospective investigation of comparative analysis with 18F-FDG

Yang, Liping; Xu, Shichuan; Cheng, Liang; Gao, Chao; Cao, Shaodong; Chang, Zhengsong*; Wang, Kezheng*哈尔滨医科大学
European Journal of Nuclear Medicine and Molecular Imaging2023-11DOI: 10.1007/s00259-023-06351-9
1被引7阅读
引用收藏
分享

摘要

PurposeThe radiopharmaceutical [F-18]AlF-NOTA-FAPI-04 presents a promising alternative to (68) Ga-FAPI owing to its relatively longer half-life. This study aimed to evaluate the clinical usefulness of [F-18]AlF-NOTA-FAPI-04 PET/CT for the diagnosis of primary and metastatic lesions in various types of gastrointestinal system cancers, compared with F-18-FDG PET/CT.MethodsPatients diagnosed with gastrointestinal system malignancies were prospectively enrolled. All patients underwent both F-18-FDG and F-18-FAPI-04 PET/CT scans within one week, with 44 (73.3%) for cancer staging and 16 (26.7%) for tumor restaging. Diagnostic efficacy of the primary tumor, as well as the presence and number of lymph nodes and distant metastases, were assessed. Tumor uptake was quantified by the maximum standard uptake value (SUVmax).ResultsFor detection of primary tumor, the diagnostic sensitivity of F-18-FDG PET/CT was 72.7%, while it was 97.7% for F-18-FAPI-04 PET/CT. Based on per-lymph node analysis, the sensitivity, specificity, and accuracy of F-18-FAPI-04 PET/CT in diagnosing metastatic lymph nodes were 91.89%, 92.00%, and 91.96%, respectively. These values were notably higher than those F-18-FDG PET/CT (79.72%, 81.33% and 80.80%, respectively). The F-18-FAPI-04 PET/CT surpassed F-18-FDG PET/CT in detecting suspected metastases in the brain (7 vs. 3), liver (39 vs. 20), bone (79 vs. 51), lung (11 vs. 4), and peritoneal carcinoma (48 vs. 22). Based on per-patient analysis, differential diagnostic accuracies (F-18-FAPI-04 vs. F-18-FDG PET/CT) were observed in all patients (91.7% vs. 76.7%), the initial staging group (90.9% vs. 79.5%), and the re-staging group (93.8% vs. 68.7%). Additionally, F-18-FAPI-04 PET/CT revised final diagnosis in 31.7% of patients, contrasting with F-18-FDG PET/CT, and prompted changes in clinical management for 21.7% of the patients.Conclusion(18)F-FAPI-04 PET/CT outperforms F-18-FDG PET/CT in delineating the primary gastrointestinal tumors and detecting suspected metastatic lesions due to a higher target-to-background ratio (TBR). Moreover, F-18-FAPI-04 PET/CT could provide valuable guidance for tumor staging, thereby having a potential impact on patient management.

学科与关键词

关键词
Gastrointestinal system cancersFAPI PETCTFDG PETCancer-associated fibroblastClinical management
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
European Journal of Nuclear Medicine and Molecular Imaging
发表日期
2023-11
卷期
第 50 卷, 第 13 期
页码
4051-4063
DOI
10.1007/s00259-023-06351-9
语言
ENGLISH
成果收录
SCIE

作者

  • Y

    Yang, Liping (第一作者)

    harbin med univ

  • X

    Xu, Shichuan

查看全部 7 位作者收起作者
  • C

    Cheng, Liang

    harbin med univ

  • G

    Gao, Chao

    harbin med univ

  • C

    Cao, Shaodong

    harbin med univ

  • C

    Chang, Zhengsong (通讯)

    harbin med univ

  • W

    Wang, Kezheng (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417